These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 2133250)

  • 61. Cathepsin D stimulates the activities of secreted plasminogen activators in the breast cancer acidic environment.
    Maynadier M; Farnoud R; Lamy PJ; Laurent-Matha V; Garcia M; Rochefort H
    Int J Oncol; 2013 Nov; 43(5):1683-90. PubMed ID: 24026424
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy.
    Harbeck N; Alt U; Berger U; Krüger A; Thomssen C; Jänicke F; Höfler H; Kates RE; Schmitt M
    Clin Cancer Res; 2001 Sep; 7(9):2757-64. PubMed ID: 11555589
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer.
    Jänicke F; Schmitt M; Graeff H
    Semin Thromb Hemost; 1991 Jul; 17(3):303-12. PubMed ID: 1796300
    [No Abstract]   [Full Text] [Related]  

  • 64. Plasminogen activation: biochemistry, physiology, and therapeutics.
    Wun TC
    Crit Rev Biotechnol; 1988; 8(2):131-48. PubMed ID: 2976309
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Plasminogen activator in human breast cancer cytosols: revisited after five years.
    Ng R; Sutherland DJ; Szalai JP; Kellen JA
    In Vivo; 1991; 5(4):313-6. PubMed ID: 1810415
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Prognostic value of immunohistochemical determination of urokinase plasminogen activator in primary breast cancers].
    Göhring UJ; Scharl A; Thelen U; Ahr A; Titius BR
    Pathologe; 1995 Nov; 16(6):398-403. PubMed ID: 8570558
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Breast-conserving therapy: proteases as risk factors in relation to survival after local relapse.
    Meijer-van Gelder ME; Look MP; Bolt-de Vries J; Peters HA; Klijn JG; Foekens JA
    J Clin Oncol; 1999 May; 17(5):1449-57. PubMed ID: 10334530
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Low cathepsin D and low plasminogen activator type 1 inhibitor in tumor cytosols defines a group of node negative breast cancer patients with low risk of recurrence.
    Kute TE; Grøndahl-Hansen J; Shao SM; Long R; Russell G; Brünner N
    Breast Cancer Res Treat; 1998 Jan; 47(1):9-16. PubMed ID: 9493971
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (Pro-uPA).
    Kobayashi H; Schmitt M; Goretzki L; Chucholowski N; Calvete J; Kramer M; Günzler WA; Jänicke F; Graeff H
    J Biol Chem; 1991 Mar; 266(8):5147-52. PubMed ID: 1900515
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Biological and clinical significance of cathepsin D in breast cancer.
    Rochefort H
    Semin Cancer Biol; 1990 Apr; 1(2):153-60. PubMed ID: 2103491
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Urokinase plasminogen activator, a strong independent prognostic factor in breast cancer, analysed in steroid receptor cytosols with a luminometric immunoassay.
    Fernö M; Bendahl PO; Borg A; Brundell J; Hirschberg L; Olsson H; Killander D
    Eur J Cancer; 1996 May; 32A(5):793-801. PubMed ID: 9081356
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Urokinase plasminogen activator as a prognostic marker in different subgroups of patients with breast cancer.
    Duffy MJ; Reilly D; McDermott E; O'Higgins N; Fennelly JJ; Andreasen PA
    Cancer; 1994 Oct; 74(8):2276-80. PubMed ID: 7922979
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Role of plasminogen activators in cancer dissemination. Clinical perspectives].
    Alonso DF; Bal de Kier Joffé E
    Medicina (B Aires); 1992; 52(3):252-6. PubMed ID: 1342692
    [No Abstract]   [Full Text] [Related]  

  • 74. E-cadherin and urokinase-type plasminogen activator tissue status in gastric carcinoma.
    Yonemura Y; Nojima N; Kaji M; Fujimura T; Itoh H; Ninomiya I; Miyazaki I; Endo Y; Sasaki T
    Cancer; 1995 Sep; 76(6):941-53. PubMed ID: 8625219
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Clinical relevance of prognostic factors in axillary node-negative breast cancer.
    Thomssen C; Jänicke F; Harbeck N
    Onkologie; 2003 Oct; 26(5):438-45. PubMed ID: 14605459
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Effective activation of the proenzyme form of the urokinase-type plasminogen activator (pro-uPA) by the cysteine protease cathepsin L.
    Goretzki L; Schmitt M; Mann K; Calvete J; Chucholowski N; Kramer M; Günzler WA; Jänicke F; Graeff H
    FEBS Lett; 1992 Feb; 297(1-2):112-8. PubMed ID: 1551416
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Tissue plasminogen activator (t-PA) and urokinase plasminogen activator (u-PA)].
    Kondo S
    Nihon Rinsho; 2004 Dec; 62 Suppl 12():700-2. PubMed ID: 15658428
    [No Abstract]   [Full Text] [Related]  

  • 78. Multiparametric prognostic evaluation of biological factors in primary breast cancer.
    Spyratos F; Martin PM; Hacène K; Romain S; Andrieu C; Ferrero-Poüs M; Deytieux S; Le Doussal V; Tubiana-Hulin M; Brunet M
    J Natl Cancer Inst; 1992 Aug; 84(16):1266-72. PubMed ID: 1640487
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Urokinase plasminogen activator: a prognostic marker in multiple types of cancer.
    Duffy MJ; Maguire TM; McDermott EW; O'Higgins N
    J Surg Oncol; 1999 Jun; 71(2):130-5. PubMed ID: 10389872
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Urokinase plasminogen activator as a predictor of aggressive disease in breast cancer.
    Duffy MJ; Duggan C; Maguire T; Mulcahy K; Elvin P; McDermott E; Fennelly JJ; O'Higgins N
    Enzyme Protein; 1996; 49(1-3):85-93. PubMed ID: 8796999
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.